1. Introduction {#s0005}
===============

Autonomic imbalance, defined by increased heart rate (HR) and decreased heart rate variability (HRV), is associated with increased morbidity and mortality in patients with various diseases ([@bb0105]). Autonomic imbalance has been demonstrated in autoimmune diseases like rheumatoid arthritis (RA), systemic lupus erythematosus, ankylosing spondylitis and inflammatory bowel disease ([@bb0025], [@bb0035], [@bb0170]), where it has traditionally been considered a result of chronic inflammation. In RA, a prototypic immune-mediated inflammatory disease, several studies demonstrated reduced activity of the parasympathetic nervous system (PNS), whereas others found an overactive sympathetic nervous system in RA patients ([@bb0005], [@bb0120]). HRV measurements were also shown to predict response to biological treatment in RA patients ([@bb0095]). These observations are relevant because activation of the PNS via stimulation of the vagus nerve and the nicotinic acetylcholine receptor type 7 (α7nAChR) can reduce inflammation, which has been termed as the cholinergic anti-inflammatory pathway ([@bb0040], [@bb0185]). In addition to measurement of HRV, assessment of sympathetic nervous system (SNS)-related hormones, such as epinephrine and norepinephrine, is informative about autonomic dysfunction ([@bb0100], [@bb0190]).

We postulated that autonomic dysfunction may precede the development of RA, which would suggest that it plays a role in the etiopathogenesis of this disease. Previous studies in healthy individuals have shown that decreased HRV parameters are associated with development of disease, such as hypertension and diabetes, as an independent risk factor ([@bb0175]). Individuals at risk of developing autoantibody positive RA can be identified by detection of the autoantibodies IgM-rheumatoid factor (IgM-RF) and anti-citrullinated protein antibodies (ACPA); the risk of developing arthritis is further increased by smoking, overweight and genetic factors ([@bb0115], [@bb0070]). Not all identified individuals will develop RA, but the presence of multiple serum autoantibodies increases the risk of developing RA in two years up to \~ 40% ([@bb0045]). Identification of additional risk factors is necessary to provide insight into pathogenic mechanisms contributing to the development of clinically manifest disease, and might also lead to development of preventive strategies.

To evaluate whether autonomic dysfunction might contribute to the development of RA rather than being the result of chronic inflammation, we measured HRV as well as plasma levels of (nor)epinephrine, and the expression of α7nAChR on peripheral blood monocytes in individuals at risk of developing RA, healthy subjects and RA patients. In a validation cohort, we examined the relationship between heart rate at baseline and development of RA after follow-up.

2. Materials & Methods {#s0010}
======================

2.1. Study Subjects {#s0015}
-------------------

RA patients (n = 20), healthy subjects (HS, n = 20) and individuals at risk of developing RA (AR subjects, n = 50) were included in a prospective observational study (study cohort). A sample size calculation was performed, whereby 18 subjects in the RA and HS groups would have 80% power to detect a difference in mean high frequency (HF) of 14.6 assuming a standard deviation (SD) of 15 ([@bb0060]) using a two group t-test with 0.05 two-sided significance level. We expected a smaller difference between HS and AR subjects, and RA and AR subjects, and have therefore included more AR subjects. AR subjects were defined as being positive for IgM-RF, ACPA or both, having either arthralgia, or a positive family history for RA (phase (c) + (d) or (c) + (a), but without any evidence of arthritis upon standardized physical examination according to European League Against Rheumatism (EULAR) recommendations ([@bb0065], [@bb0165]). RA patients were classified according to the 2010 American College of Rheumatology and EULAR classification criteria ([@bb0010]) and had arthritis in at least one joint, despite a stable dose of methotrexate and in some patients prednisone (n = 4, median dose 6.25 mg per day, interquartile range (IQR) 5--9.4 mg per day) for at least one month. HS were negative for IgM-RF and ACPA. Individuals with a history of cardiovascular or neurological disease, diabetes, anti-hypertensive treatment, active infection or use of antibiotics in the 7 days preceding study assessments were excluded. The study was performed according to the principles of the Declaration of Helsinki, approved by the institutional review board of the Academic Medical Center (AMC), the Netherlands (reference NL34802.018.10), and all study subjects gave written informed consent.

A second, independent at risk (AR) cohort (validation cohort) was used to validate the results. This cohort was started at the Department of Clinical Immunology and Rheumatology AMC in 2005 and has been described before ([@bb0050], [@bb0055]). Similar in- and exclusion criteria were used as described above.

2.2. Study Design {#s0020}
-----------------

In the study cohort, during one single visit demographics, anthropometric data, smoking and alcohol status, medical history, RA medication history and current medication were obtained between 8:30 and 10 am, after patients had fasted for 8 to 10 h. Continuous heart rate (HR) and blood pressure (BP) measurements were obtained non-invasively using finger arterial pressure waveform recording of the left hand by Nexfin (Edwards Lifesciences, BMEYE B.V. Amsterdam, the Netherlands), a validated method to assess HRV parameters ([@bb0155], [@bb0150]). The recording session contained two parts: ten-minute period in supine (resting) position, and a ten-minute period of orthostatic stress in upright (active) position. Individuals were allowed to equilibrate to the positional change before data were collected, followed by assessment of RA disease activity (Disease Activity Score of 28 joints (DAS28) with erythrocyte sedimentation rate (ESR) ([@bb0150])) and a blood draw.

In the validation cohort we determined vital signs at yearly visits, including resting heart rate (RHR) in sitting position, using an automated monitor system. This measurement took place in non-fasting state either in the morning or the afternoon.

2.3. Analysis of Heart Rate Variability Parameters {#s0025}
--------------------------------------------------

HRV recordings were analyzed as described before ([@bb0155]) according to Task Force Guidelines ([@bb0015]). A period of ≥ 250 consecutive heart beats without interfering signals was selected for both positions. HRV parameter analysis is categorized into time and frequency domain (TD, FD) analysis. TD parameters are: HR, BP, respiratory rate (RR), standard deviation of all beat-to-beat intervals (SDNN) and root mean square of successive differences (RMSSD). RHR and SDNN are mainly influenced by the PNS, while in upright position the SNS becomes more active. RMSSD reflects PNS activity in both positions. FD parameters of the pulse interval were determined as described before ([@bb0200]) by in-house developed digital Fourier transform (DFT, Matlab, courtesy W.J. Stok, MSc). The FD parameter for PNS is HF (0.15--0.40 Hz) and of both SNS and PNS are low frequency (LF: 0.04--0.15 Hz) and LF/HF ratio. LF expressed in normalized units (nu) instead of ms^2^ shows the influence of the SNS more distinctly, as it is controlled for total power and very low frequency (TP and VLF) ([@bb0015]). Furthermore, gain of the baroreceptor reflex sensitivity (BRS) was calculated from the transfer from systolic BP to heart period in the LF-band, representing ability of the cardiovascular system to counteract beat-to-beat changes in BP. Overall, lowered vagal efferent results in lower HRV parameters, except for HR, RR and LF/HF ratio which increase.

2.4. Measurement of Norepinephrine, Epinephrine and α7nAChR Expression in Peripheral Blood {#s0030}
------------------------------------------------------------------------------------------

Norepinephrine and epinephrine in peripheral blood could be measured in 16/20 (80%) HS, 43/50 (86%) AR subjects and 19/20 (95%) RA patients from the study cohort. Fourteen AR subjects gave informed consent for additional peripheral blood samples to measure α7nAChR expression on monocytes. Assays are described in the Methods Appendix.

2.5. Statistics {#s0035}
---------------

Data are presented as median with IQR. Demographic data from individuals enrolled in the study and validation cohorts were analyzed with non-parametric tests (Kruskal--Wallis test, Mann--Whitney U test) if not normally distributed or by parametric tests (analysis of variance (ANOVA), Student\'s t-test) if normally distributed. Categorical demographic variables were tested using Pearson\'s Chi-Square test. HRV parameters and SNS-related hormones were analyzed using multivariate linear regression analysis with following confounding factors: age, gender, body mass index (BMI), smoking pack years and plasma triglycerides. Confounders were chosen based on the literature ([@bb0180]) and differences between the groups in the study cohort. The study cohort was designed to evaluate changes in AR subjects compared to RA patients and HS rather than to compare RA and HS. In the validation cohort Cox\'s proportional hazard regression analysis was performed to evaluate the association of RHR with arthritis development, taking follow-up time and the following potentially confounding factors into account: age, gender, BMI and smoking pack years. Plasma triglycerides were available in a subset of individuals from the validation cohort and these were not included as confounder. Medication was considered as confounding factor as well. There is no known influence of disease-modifying antirheumatic drugs (DMARDs), or prednisone on HRV parameters. Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to influence the cardiovascular system ([@bb0030], [@bb0020]) and could therefore influence HRV. Adding NSAIDs as a confounder did not alter results of the study in either cohort, and was therefore not included in the multivariate regression analysis. SNS-related hormones are not influenced by DMARD or NSAID use, but prednisone use may lower (nor)epinephrine levels ([@bb0085], [@bb0075]), and prednisone was included as an additional confounder in the analysis of these parameters. P-values \< 0.05 were considered statistically significant.

2.6. Role of the Funding Source {#s0040}
-------------------------------

The study was funded by the FP7 HEALTH program under grant agreement FP7-HEALTH-F2-2012-305549 and the Dutch Arthritis Foundation grant 09-1-307. None of the funding sources had any role in design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript.

3. Results {#s0045}
==========

3.1. Demographics Study Cohort {#s0050}
------------------------------

Demographics of the study cohort are described in [Table 1](#t0005){ref-type="table"}. As expected, AR subjects tended to be younger than RA patients. Significantly more 'ever smoker\'s' and 'smoking pack years' were identified in AR subjects and RA patients compared to HS. Plasma triglyceride levels were higher in AR subjects and RA patients than in HS, but there was no difference in other lipid levels. RA patients had active disease, as defined by DAS28 above 3.2 ([@bb0150]). The mean follow-up time of study cohort was 18.2 months (standard deviation (SD) 7.6 months) during 4/50 individuals (8%) developed arthritis.

3.2. Lower Parasympathetic Activity in AR Subjects {#s0055}
--------------------------------------------------

AR subjects (study cohort) had a significantly higher RHR (68 beats per minute (bpm)) compared to HS (60 bpm, p = 0.006), and similar RHR compared to RA patients (68 bpm, p = 0.38, [Fig. 1](#f0005){ref-type="fig"}A, [Table 2](#t0010){ref-type="table"}). HR in upright position was also significantly higher in AR subjects than in HS (80 bpm versus 75 bpm, p = 0.045), and similar to RA patients (81 bpm). Elevated RHR is mainly a consequence of lower PNS (vagus tone) activity and elevated HR in upright position is a result of autonomic imbalance with lower PNS and higher SNS activity. Other HRV parameters in AR subjects were numerically lower compared to HS, but still higher compared to RA patients ([Table 2](#t0010){ref-type="table"}), indicating that the autonomic changes in the AR subjects were not as pronounced on group level compared to the RA group. This would be consistent with the fact that not all AR subjects will develop disease. Next we used a cut-off rate for RHR of 70 bpm, as previous work has shown that RHR ≥ 70 bpm is an undesirable prognostic sign for morbidity and mortality in cardiovascular studies ([@bb0105]). RHR was ≥ 70 bpm in 3/20 (15%) of the HS, 20/50 (40%) of AR subjects and 10/20 (50%) of RA patients. When dichotomizing AR subjects at RHR of 70, it became clear that those with a RHR ≥ 70 bpm displayed lower parasympathetic activity with significantly lower SDNN, RMSSD, LF (ms^2^), HF (ms^2^) and BRS in both positions. LF (nu), HF (nu), MAP, RR and LF/HF ratio were not altered ([Table 3](#t0015){ref-type="table"}).

3.3. Higher Risk of Arthritis Development With Increased Heart Rate at Baseline {#s0060}
-------------------------------------------------------------------------------

Having shown higher resting HR in AR subjects in the study cohort, we next evaluated RHR in a similar, independent validation cohort, and related RHR at baseline to development of arthritis. Demographics of the validation cohort are shown in Appendix Table 1; 14/45 (31.1%) individuals developed arthritis after follow-up (31.7 months, SD 25.0 months). RHR at baseline was significantly higher in individuals who developed arthritis after follow-up (n = 14, 73.8 vs 65.8 bpm, p = 0.018, [Fig. 1](#f0005){ref-type="fig"}B) compared to those who did not develop arthritis during follow-up (n = 31). In a Cox\'s regression analysis, taking follow-up time and confounders in consideration, RHR was associated with arthritis development over time (hazard ratio 1.098: 95% CI 1.012--1.191, p = 0.025). Thus, these data are consistent with the notion that altered autonomic function precedes the development of clinically manifest RA.

3.4. Lower α7nAChR Expression in AR Subjects with RHR ≥ 70 bpm {#s0065}
--------------------------------------------------------------

AR subjects with RHR ≥ 70 bpm (n = 6) had significantly lower α7nAChR expression levels on peripheral blood monocytes (p = 0.013) than AR subjects with RHR \< 70 bpm (n = 8), consistent with decreased activity of the cholinergic anti-inflammatory reflex. Alpha-7nAChR was expressed on 47% (IQR 36.3--54.6) of monocytes in AR subjects with RHR ≥ 70 bpm, while in AR subjects with RHR \< 70 bpm 69.6% (IQR 64.9--73.5) of monocytes were positive for α7nAChR ([Fig. 2](#f0010){ref-type="fig"}).

3.5. Hormonal Changes: AR Subjects Have Increased Norepinephrine Levels {#s0070}
-----------------------------------------------------------------------

Norepinephrine levels were higher in AR subjects compared to HS (p = 0.012), and there was a non-significant trend towards higher levels compared to RA patients ([Table 4](#t0020){ref-type="table"}). There was no difference in epinephrine levels between the groups.

3.6. Lower Parasympathetic Activity in Established RA Patients {#s0075}
--------------------------------------------------------------

RA patients had significantly higher HR in both positions (supine: p = 0.002, upright: p = 0.010) compared to HS, indicating less PNS activity. SDNN, RMSSD, HF and BRS were all lower in RA compared to HS ([Table 2](#t0010){ref-type="table"} and Appendix Table 2) in upright position. LF (ms^2^) was significantly lower in RA patients compared to HS and AR subjects in upright position, but evaluating LF (nu) did not show significant changes.

4. Discussion {#s0080}
=============

Results presented here show that lower parasympathetic activity, as revealed by lower HRV and elevated RHR in AR subjects and RA patients compared to healthy subjects. Decreased vagus nerve tone was similar in AR subjects and established RA patients. In a similar, independent validation cohort RHR was significantly higher in individuals who subsequently developed arthritis. AR subjects with RHR ≥ 70 bpm demonstrate lower α7nAChR levels on peripheral monocytes than AR subjects with RHR \< 70 bpm. Furthermore, the sympathetic hormone norepinephrine is elevated in AR subjects. Taken together, these prospective observational studies indicate an altered autonomic function preceding the development of clinically manifest disease, which could therefore be part of the pathogenesis of RA development.

In the resting state, HR is mostly under inhibitory control by the PNS, while in active, upright position the SNS becomes more active to the vasculature and their balance regulates appropriate HR increase ([@bb0180]). Elevated RHR in AR subjects and RA patients clearly indicates lower parasympathetic activity compared to HS. HRV parameters are dependent on HR; e.g. increased HR results in decreased HRV parameters ([@bb0135]). Elevated RHR (≥ 70 bpm) is therefore accompanied by significantly lower HRV parasympathetic parameters in both positions. Increased RHR at baseline was associated with subsequent arthritis development, as we could show in an independent cohort of individuals at risk of RA.

Expression levels of the parasympathetic receptor α7nAChR on peripheral blood monocytes could be evaluated in a subset of AR subjects. Expression levels were significantly decreased in individuals with RHR ≥ 70 bpm compared to those with RHR \< 70 bpm. Alpha-7nAChR is expressed on many different immune cells ([@bb0120]); it is currently not known how expression levels are regulated. Binding of acetylcholine, produced by the vagus nerve (PNS) and immune cells, to α7nAChR has an immunosuppressive effect ([@bb0125]). Decreased levels of α7nAChR are in line with reduced activity of the cholinergic anti-inflammatory reflex preceding the development of clinically manifest RA.

Levels of the sympathomimetic hormone norepinephrine were significantly increased in AR subjects compared to HS, and there was a trend towards higher levels compared to RA patients. Norepinephrine levels in peripheral blood depend on release, turn over and clearance, and may with care be interpreted as an estimate of overall sympathetic activity ([@bb0005]). Norepinephrine levels in established RA have been reported to be increased ([@bb0100], [@bb0190]) or similar compared to HS ([@bb0145], [@bb0195]). The role of increased norepinephrine levels in AR subjects is not clear. Catecholamine depletion before onset of arthritis in animal models of RA has an anti-inflammatory effect, suggesting that catecholamines may promote the immune response before onset of disease ([@bb0120]). In our study norepinephrine levels are relatively low, which could result in activation of the alpha adrenergic receptor types (α-AR), mainly expressed on innate immune cells ([@bb0120]). Activation of α-AR could result in a more pro-inflammatory status, but data are limited ([@bb0120]). Epinephrine levels tend to be lower ([@bb0100], [@bb0190]) in RA compared to healthy controls or show similar levels ([@bb0195], [@bb0090]). In our study we did not find differences in epinephrine levels between the groups.

Several studies have evaluated the autonomic balance in established RA patients and demonstrated autonomic changes using various HRV parameters ([@bb0025], [@bb0060], [@bb0080], [@bb0130]). Most of these studies did not adjust for confounding factors of HRV parameters with multivariable analysis, despite known influence of confounders, such as age and sex identified in large cohorts ([@bb0180]). In our study PNS activity was attenuated in RA patients compared to HS, as HR was significantly higher in both positions. As a result, other HRV parameters were lowered, but only statistically significant in active position. LF (nu) as a more distinct parameter of the SNS was higher in RA patients at rest, but the difference did not reach statistical significance. Overall, these findings are consistent with decreased parasympathetic activity in RA patients with little indication of an overactive sympathetic system, which is in line with the literature ([@bb0005]).

A limitation of this study is that continuous BP and HR measurements were only available in the study cohort. However, automated BP and HR measurements are also used in other studies and we were able to show excellent correlation between continuous and automated BP and HR measurements in the study cohort (Pearson\'s test r = 0.78, p \< 0.001), indicating that single BP and HR measurements provide reliable data. Finally, we did not investigate the level of physical activity or chronic stress in the study subjects, which could have provided interesting information with regard to the cause of the decreased vagus nerve activity.

Data presented here are consistent with a pathogenic role of the autonomic nervous system in the development of RA. Could these findings help to develop preventive strategies? It is tempting to speculate that decreasing RHR by for instance exercise or meditation ([@bb0110], [@bb0140], [@bb0160]) could reduce the risk of transition of preclinical RA to clinically manifest RA. Alternatively, a bioelectronics approach aimed at stimulation of the vagus nerve might be explored as a preventive intervention in subjects at high risk of developing RA ([@bb0125]). Clearly, the possible value of such interventions needs to be demonstrated in future studies.

In conclusion, we have found that autonomic imbalance precedes the development of established RA, which could also be relevant for other immune-mediated inflammatory diseases. This work supports the rationale for future studies on measures aimed at prevention of RA by restoring the balance in the nervous system before arthritis develops.
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![Resting heart rate in healthy subjects, AR subjects and RA patients (A) and resting heart rate in AR subjects that developed arthritis after follow-up (B).\
Abbreviations: AR: at risk, HS: healthy subjects; RA: rheumatoid arthritis; bpm: beats per minute, \*p \< 0.05, \*\*p \< 0.01.](gr1){#f0005}

![Expression levels of the parasympathetic receptor, nicotinic acetylcholine receptor type 7 (α7nAChR) on peripheral blood CD14 + monocytes AR subjects with resting heart rate \< and ≥ 70 bpm.\
Abbreviations: α7nAChR: nicotinic acetylcholine receptor type 7, AR: at risk, RHR: resting heart rate, bpm: beats per minute, \*p \< 0.05.](gr2){#f0010}

###### 

Demographics study cohort.

                                HS (n = 20)         AR subjects (n = 50)   RA (n = 20)         P-value[a](#tf0005){ref-type="table-fn"}
  ----------------------------- ------------------- ---------------------- ------------------- ------------------------------------------
  Age (years)                   49 (39--56)         47 (40--53)            56 (45--64)         0.078
  Female: n (%)                 12 (60)             38 (76)                13 (65)             0.36
  BMI (kg/m^2^)                 23.8 (22.7--26.5)   25.3 (22.1--27.3)      25.9 (21.9--28.3)   0.59
  Alcohol use: n (%)            15 (75)             27 (54)                10 (50)             0.20
  Current smoker: n (%)         2 (10)              14 (28)                4 (20)              0.25
  Ever smoker: n (%)            3 (15)              21 (42)                10 (52.6)           0.038
  Cigarettes/day                0 (0--0)            0 (0--3)               0 (0--0)            0.29
  Packyears                     0.0 (0.0--0.0)      0.0 (0.0--11)          2.5 (0.0--15.0)     0.054
  Cholesterol total (mmol/L)    5.3 (4.8--6.2)      5.5 (4.7--6.3)         5.20 (4.5--5.7)     0.28
  HDL (mmol/L)                  1.8 (1.4--2.0)      1.6 (1.2--1.9)         1.5 (1.2--1.7)      0.31
  LDL (mmol/L)                  3.3 (2.6--3.8)      3.4 (2.7--4.0)         3.2 (2.7--3.7)      0.48
  Triglycerides (mmol/L)        0.7 (0.6--1.0)      0.9 (0.7--1.1)         1.1 (0.9--1.4)      0.032
  Total cholesterol/HDL ratio   3.1 (2.7--4.3)      3.5 (2.8--4.1)         3.5 (2.9--3.9)      0.71
  Glucose (mmol/L)              5.0 (4.7--5.4)      5.1 (4.8--5.4)         5.1 (4.8--5.7)      0.84
  RF positive: n (%)            0 (0)               31 (62)                15 (75)             \< 0.0001
  RF titer (kU/L)               3 (1--12)           92 (18--174)           217 (53--379)       \< 0.0001
  ACPA positive: n (%)          0 (0)               33 (66)                16 (80)             \< 0.0001
  ACPA titer (kAU/L)            4 (1--5)            96 (4--512)            220 (57--1187)      \< 0.0001
  Disease duration (months)     NA                  NA                     20 (4--91)          
  VAS GDA (mm)                  NA                  26 (13--53)            44 (25--70)         \< 0.0001
  TJC28 (n)                     0 (0--0)            1 (0--2)               5 (3--8)            \< 0.0001
  SJC28 (n)                     0 (0--0)            0 (0--0)               2 (2--4)            \< 0.0001
  ESR (mm/h)                    5 (2--11)           5 (2--10)              15 (9--27)          \< 0.0001
  CRP (mg/L)                    1.8 (1.0--2.7)      1.5 (0.8--3.9)         5.6 (1.9--10.5)     0.001
  DAS28                         NA                  NA                     4.32 (3.67--4.72)   
  NSAIDs: n (%)                 0 (0)               13 (27)                10 (50)             0.001
  Corticosteroids: n (%)        0 (0)               0 (0)                  4 (20)              \< 0.0001
  Methotrexate: n (%)           0 (0)               0 (0)                  15 (75)             \< 0.0001
  HCQ: n (%)                    0 (0)               0 (0)                  2 (10)              0.028

Abbreviations: AR: at risk, HS: healthy subjects; RA: rheumatoid arthritis; BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; RF: rheumatoid factor; ACPA: anti-citrullinated protein antibodies; VAS GDA: visual analogue scale (range 0--100 mm) global disease activity; TJC28: tender joint count of 28 joints; SJC28: swollen joint count of 28 joints; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: disease activity score of 28 joints; NSAIDs: non-steroidal anti-inflammatory drugs; HCQ: hydroxychloroquine; NA: not applicable.

Analysis with non-parametric tests (Kruskal--Wallis test) if not normally distributed or parametric tests (analysis of variance (ANOVA)) if normally distributed. Categorical demographic variables tested using Pearson\'s Chi-Square test. Data presented as median (interquartile range) or number (percentage).

###### 

Heart rate variability parameters in supine (Sup, resting) and upright (Upr, active) position in the study cohort, as measured by continuous heart rate and blood pressure recordings comparing AR subjects with HS and RA.

                       HS                AR subjects      RA                P-value[a](#tf0010){ref-type="table-fn"}                                                           
  -------------------- ----------------- ---------------- ----------------- ------------------------------------------ ---------------- --------------- ------- ------- ------ ------
  *Time domain*                                                                                                                                                                
  Heart Rate (bpm)     60 (56--63)       75 (67--79)      68 (61--73)       80 (74--87)                                68 (62--76)      81 (74--92)     0.006   0.045   0.38   0.28
  MAP (mm Hg)          85 (79--95)       95 (89--100)     88 (79--97)       96 (89--110)                               88 (79--95)      101 (87--105)   0.66    0.38    0.19   0.75
  RR (breaths/min)     14 (12--17)       13 (12--16)      14 (12--17)       14 (13--16)                                15 (11--17)      16 (14--18)     0.64    0.27    0.83   0.23
  SDNN (ms)            36 (30--46)       38 (33--42)      37 (26--52)       31 (25--41)                                26 (20--39)      26 (19--32)     0.58    0.045   0.14   0.45
  RMSSD (ms)           23 (20--45)       17 (13--22)      26 (18--38)       15 (12--20)                                21 (16--35)      11 (10--15)     0.17    0.014   0.75   0.18
                                                                                                                                                                               
  *Frequency domain*                                                                                                                                                           
  LF (ms^2^)           355 (212--492)    385 (161--827)   267 (128--704)    246 (124--465)                             154 (113--296)   113 (71--186)   0.59    0.074   0.67   0.24
  LF (nu)              31 (22--45)       44 (26--59)      30 (19--45)       40 (31--55)                                39 (27--45)      37 (27--44)     0.77    0.79    0.12   0.37
  HF (ms^2^)           286 (177--987)    181 (91--355)    313 (165--628)    155 (96--263)                              158 (124--301)   126 (60--166)   0.29    0.12    0.39   0.45
  HF (nu)              41 (25--53)       25 (16--36)      42 (32--52)       28 (22--37)                                46 (31--55)      31 (21--36)     0.26    0.46    0.43   0.85
  LF/HF ratio          0.7 (0.5--1.6)    1.6 (1.1--3.0)   0.8 (0.5--1.2)    1.5 (0.9--2.0)                             0.9 (0.4--1.5)   1.1(0.7--1.7)   0.45    0.75    0.55   0.63
  BRS (ms/mm Hg)       8.4 (5.6--12.1)   4.5 (3.5--7.4)   6.9 (4.6--10.5)   4.2 (2.6--5.5)                             5.9 (4.2--7.9)   3.1(2.5--3.7)   0.19    0.13    0.72   0.39

Abbreviations: AR: at risk subjects, HS: healthy subjects; RA: rheumatoid arthritis; Sup: supine (resting) position: Upr: upright (active) position; bpm: beats per minute; MAP: mean arterial pressure; mm Hg: millimeter of mercury; RR: respiratory rate; SDNN: standard deviation of the NN intervals; ms: milliseconds; RMSSD: the square root of the mean squared differences of successive NN intervals; LF: low frequency; nu: normalized units; HF: high frequency; BRS: baroreceptor reflex sensitivity; ms/mm Hg: milliseconds per millimeter of mercury.

Multivariate linear regression analysis comparing AR subjects with HS and RA patients taking the following confounding factors into account: age, gender, BMI, smoking pack years and plasma triglycerides. Data presented as median with interquartile range.

###### 

Resting heart rate (RHR) divided in \< and ≥ 70 beats per minute (bpm) in AR subjects (study cohort).

                       AR subjects RHR \< 70 bpm   AR subjects RHR ≥ 70 bpm   P-value[a](#tf0015){ref-type="table-fn"}                                   
  -------------------- --------------------------- -------------------------- ------------------------------------------ ------------------- ----------- -----------
  *Time domain*                                                                                                                                          
  MAP (mm Hg)          88 (78--95)                 95 (88--109)               88 (83--99)                                96 (90--112)        0.71        0.80
  RR (breaths/min)     14.2 (12--16.8)             14.7 (12.9--17.1)          13.1 (11.7--18.2)                          13.4 (12.3--16.2)   0.89        0.50
  SDNN (ms)            42.1 (33.1--62.1)           34.1 (27.6--44.9)          27.2 (21.6--37.6)                          26.1 (19.3--35.5)   \< 0.0001   \< 0.0001
  RMSSD (ms)           29.4 (20.1--53.6)           16.3 (13.5--23.4)          19.4 (13.1--31.8)                          12.5 (9.7--18)      \< 0.0001   0.002
                                                                                                                                                         
  *Frequency domain*                                                                                                                                     
  LF (ms^2^)           327 (197--986)              362 (174--588)             194 (64--465)                              175 (86--344)       0.003       0.012
  LF (nu)              25 (17--41)                 44 (27--59)                35 (21--48)                                38 (31--48)         0.19        0.62
  HF (ms^2^)           491 (247--1210)             162 (111--316)             192 (98--407)                              127 (67--231)       \< 0.0001   0.022
  HF (nu)              41 (29--54)                 26 (22--34)                43 (33--49)                                32 (24--38)         0.32        0.63
  LF/HF ratio          0.71 (0.47--1.16)           1.74 (0.93--2.6)           0.87 (0.47--1.38)                          1.24 (0.95--1.73)   0.12        0.68
  BRS (ms/mm Hg)       9.3 (6.7--15.5)             5.1 (3.6--6.1)             4.6 (3.5--6.7)                             2.7 (2.1--4.4)      \< 0.0001   \< 0.0001

Abbreviations: AR: at risk, RHR: resting heart rate; bpm: Sup: supine (resting) position: Upr: upright (active) position; bpm: beats per minute; MAP: mean arterial pressure; mmHg: millimeter of mercury; RR: respiratory rate; SDNN: standard deviation of the NN intervals; ms: milliseconds; RMSSD: the square root of the mean squared differences of successive NN intervals; LF: low frequency; nu: normalized units; HF: high frequency; BRS: baroreceptor reflex sensitivity.

Multivariate linear regression analysis with age, gender, BMI, smoking pack years and plasma triglycerides as confounders. Data presented as median with interquartile range.

###### 

Levels of the sympathetic hormones norepinephrine and epinephrine, measured in venous blood samples of the study cohort.

                            HS                  AR subjects         RA[b](#tf0025){ref-type="table-fn"}   P-value[a](#tf0020){ref-type="table-fn"} HS vs at risk   P-value[a](#tf0020){ref-type="table-fn"} at risk vs RA
  ------------------------- ------------------- ------------------- ------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Norepinephrine (nmol/L)   2.15 (1.55--2.60)   3.02 (2.42--4.20)   2.41 (1.43--2.89)                     0.012                                                    0.056
  Epinephrine (nmol/L)      0.14 (0.06--0.17)   0.16 (0.05--0.24)   0.17 (0.03--0.35)                     0.43                                                     0.33

Abbreviations: AR: at risk, HS: healthy subjects; RA: rheumatoid arthritis; nmol/L: nanomoles/liter.

Multivariate linear regression analysis using age, gender, BMI, smoking pack years, plasma triglycerides and prednisone use as confounding factors. Data presented as median with interquartile range.

Levels of sympathetic hormones with and without prednisone use in RA patients are as follows (median with interquartile range): norepinephrine 1.57 (1.18--1.94) vs 2.45 (1.53--4.38) nmol/L; epinephrine 0.03 (0.03--0.10) vs 0.26 (0.10--0.41) nmol/L.

[^1]: Current affiliation: GlaxoSmithKline, Cambridge, United Kingdom.

[^2]: Current affiliations also: University of Cambridge, Cambridge, United Kingdom; University of Ghent, Ghent, Belgium; and GlaxoSmithKline, Stevenage, United Kingdom.
